ClinicalTrials.gg
CompletedNCT05610657Updated Sep 21, 2023

A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function

A Phase 1 interventional study of Mitapivat in Moderate Hepatic Impairment, sponsored by Agios Pharmaceuticals, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jul 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The primary purpose of this study is to compare the pharmacokinetics (PK) of a single oral dose of mitapivat in participants with moderate hepatic impairment to that in matched healthy control participants with normal hepatic function.

02

Conditions studied

  • Moderate Hepatic Impairment

Keywords

  • AG-348
  • Healthy Volunteer
  • Hepatic Impairment
  • pharmacokinetic
03

In context

Lead sponsor

Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For all Participants-

  • Age: between 18 and 65 years of age;
  • Men and women of any race;
  • (BMI) between 18.0 and 34.0 kilograms per square meter (kg/m\^2), inclusive with at least 50 kg of body weight;
  • There should be no use of tobacco- or nicotine-containing products within 3 months prior to check-in until completion of the follow-up visit;
  • Male participants must agree not to donate sperm from check-in until 90 days after completion of the follow-up visit;
  • Females of will agree to use ;
  • Able to comprehend the requirements of the study and willing to sign an form before any study related procedures are conducted and to abide by the study restrictions.

For Participants with Normal Hepatic Function-

  • In good health, determined by no (CS) findings, as determined by the investigator, from medical and surgical history, physical examination, 12-lead , vital signs measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [e.g., suspicion of Gilbert's syndrome based on total and direct ] is not acceptable) at screening and check-in;
  • Serum electrolytes (sodium, potassium, chloride, bicarbonate, magnesium, and calcium) within normal limits or if deemed not CS by the investigator judgment in the case of minor abnormalities;
  • Matched to participants with moderate hepatic impairment in sex, age (±10 years), and BMI (±20%).

For Participants with Moderate Hepatic Impairment-

  • Diagnosis of chronic (≥3 months prior to screening) and stable hepatic insufficiency (no acute episodes of illness or deterioration in hepatic function) as assessed by the investigator with a C-P classification score of 7 to 9 (moderate hepatic impairment). Evidence of liver disease should be corroborated by medical history;
  • Have current, or a history of at least 1 physical sign consistent with a clinical diagnosis of liver cirrhosis;
  • Other than hepatic insufficiency with features of cirrhosis, hepatic impairment participants are in good health and clinically stable based on:

    • stable hepatic function is defined as no recent [i.e., within the preceding 14 days] CS change in disease status according to the investigator's clinical judgment (e.g., no worsening of clinical signs of hepatic impairment, or no worsening of total bilirubin or prothrombin by more than 50%).
    • the investigator's assessment including medical history and surgical history review, a defined complete physical examination, 12-lead ECG, vital signs, and clinical laboratory evaluations (clinical chemistry [including liver function tests], hematology, urinalysis, coagulation tests, thyroid function tests).
  • Abnormal laboratory values (hepatic and nonhepatic) must be clinically acceptable by the investigator (or designee);
  • Participants who need concomitant medications that are not prohibited during this study must have a medication regimen considered to be stable by the investigator. (e.g., no new drugs or significant changes to dosage(s) within 2 weeks [or 5 half-lives, whichever is longer] prior to study drug administration on Day 1; no changes expected during study conduct). Concomitant medications must be reviewed and approved by the investigator and Labcorp medical monitor (or designee).
  • Anemia secondary to hepatic disease will be acceptable if is ≥8 grams per deciliter (g/dL) and anemia symptoms are not CS;
  • Participants must have a count ≥35 × 10\^9/L.

Exclusion criteria

Exclusion Criteria:

For all Participants-

  • Presence or history of any disorder that may prevent the successful completion of the study;
  • Participant is pregnant or breastfeeding;
  • Significant acute, new-onset illness (e.g., flu, gastroenteritis) within 2 weeks prior to dosing;
  • Inability to swallow medication;
  • Has a history of relevant drug and/or food allergies (i.e., allergy to study drug or [microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, mannitol, magnesium stearate, and the Opadry Blue II film-coat [hypromellose, titanium dioxide, lactose monohydrate, triacetin, and FD\&C Blue #2]);
  • Surgical or medical history that, in the opinion of the investigator, may potentially interfere with study drug absorption, distribution, metabolism, and/or excretion. Participants who have undergone abdominal surgery or any other major surgical procedure within 6 months prior to screening, must not be enrolled; The investigator should be guided by evidence of any of the following:

    1. History of inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal bleeding within the past 3 months.
    2. History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection.
    3. History of pancreatic injury or pancreatitis in the past 6 months; indications of impaired pancreatic function/injury as indicated by CS abnormal lipase or amylase.
    4. History of urinary obstruction or difficulty in voiding in the past 3 months.
  • History or a presence of any , with the exception of a malignancy that has been curatively treated and for which the Participant has displayed no evidence of disease within 12 months prior to screening. Current or history of hepatic carcinoma, hepatorenal syndrome, portacaval shunt surgery, or pleural effusion. Malignancy, including leukemia and lymphoma, within the last 5 years. Participants with localized, fully-treated carcinoma of the skin may be allowed with investigator (or designee) approval;
  • Confirmed (e.g., 2 consecutive measurements) systolic blood pressure >150 or \<90 millimeters of mercury (mmHg), diastolic blood pressure >100 or \<50 mmHg, and pulse rate >100 or \<40 beats per minute (bpm); (Note: Participants with vital signs outside the above ranges may be eligible if the investigator and Labcorp medical monitor deem the results are not CS.)
  • cardiac history or presence of findings as determined by the investigator at screening and check-in, including any of the following:

    1. Abnormal sinus rhythm (heart rate [HR] lower than 40 bpm and higher than 100 bpm)
    2. Risk factors for torsades de pointes (e.g., heart failure, cardiomyopathy, or family history of long syndrome)
    3. Sick sinus syndrome, second- or third-degree atrioventricular block myocardial infarction, pulmonary congestion, cardiac arrhythmia, prolonged QT interval, or conduction abnormalities.
    4. QT interval corrected for HR using Fridericia's formula (QTcF) >450 milliseconds (msec) (healthy male participants) or >470 msec (healthy female participants) or >480 msec for hepatically impaired participants; in the event a QTcF value is outside of the reference range, it will be confirmed by 2 repeat measurements, which will then be used to calculate a mean from the original value and the 2 repeat measurements.
    5. QRS interval >110 msec, confirmed by manual over read.
    6. PR interval \<120 and >220 msec.
    7. Repeated or frequent syncope or vasovagal episodes.
    8. Hypertension, angina, bradycardia (if assessed as CS by the investigator), or severe peripheral arterial circulatory disorders.
    9. History of autonomic dysfunction.
  • Has estimated \<60 mL/minute/1.73 m\^2 using equation;
  • Administration of a coronavirus disease 2019 vaccine in the past 14 days prior to dosing;
  • Has a positive test for severe acute respiratory syndrome coronavirus 2; Note: Testing will be performed according to site procedures;
  • Has an active infection requiring systemic antimicrobial therapy at any time during the screening period;
  • Is currently enrolled in or has participated in another clinical study to receive any or marketed product or placebo within 4 weeks (or 5 half-lives, whichever is longer) or longer as required by local regulations prior to check-in;
  • History of alcohol abuse within 3 months prior to screening and/or alcohol consumption of >21 units per week for males and >14 units for females. One unit of alcohol equals 12 ounce [oz] (360 mL) beer, 1 1/2 oz (45 mL) liquor, or 5 oz (150 mL) wine;
  • Positive urine, breath, or blood test for alcohol or positive urine drug screen at screening and/or check-in;
  • Positive urine cotinine test screening and/or at check-in (smokers will be defined as any participant who reports current tobacco use and/or who has a positive urine cotinine test);
  • History or suspicion of active substance use disorder prior to check-in (including, but not limited to: cannabinoids, amphetamines, methamphetamines, 3,4-methylenedioxy-N-methylamphetamine [ecstasy], opiates, methadone, oxycodone, phencyclidine, cocaine, cotinine, benzodiazepines, and barbiturates);
  • Ingestion of poppy seed-, Seville orange-, or grapefruit-containing foods or beverages within 7 days prior to check-in and not willing to refrain from consumption of these foods or beverages throughout the study until completion of the follow-up visit;
  • Alcohol consumption, starting 48 hours prior to check-in and continuing until completion of the follow-up visit;
  • Consumption of caffeine- or xanthine-containing products within 48 hours before check-in until completion of the follow-up visit;
  • Consumption of vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussel sprouts, and mustard greens), or charbroiled meat for 7 days prior to dosing until completion of the follow-up visit;
  • Receipt of blood products within 2 months prior to check-in;
  • Participant has donated (or lost) ≥ 400 mL of red blood cells within 2 months prior to screening, plasma within 2 weeks prior to screening, or within 6 weeks prior to screening; Participant has planned donation of any blood products after screening until 3 months after the follow-up visit;
  • Participants are required to refrain from strenuous exercise from 7 days before check-in until completion of the follow-up visit and will otherwise maintain their normal level of physical activity during this time (i.e., will not begin a new exercise program nor participate in any unusually strenuous physical exertion);
  • Poor peripheral venous access;
  • Participants who, in the opinion of the investigator (or designee), should not participate in this study;
  • Positive surface antigen or 1 or 2 test.

For Participants with Normal Hepatic Function-

  • Liver test results (, aspartate aminotransferase, alkaline phosphatase, albumin, or total ) above the and/or prolonged (results may be repeated once), at screening and check-in, unless deemed not CS approved by the investigator (or designee);
  • Has a known history or presence of liver disease;
  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder (as determined by the investigator);
  • Uses or intends to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including slow-release medications/products, any over-the-counter medications or herbal or nutritional supplements with the exception of vitamins, within 14 days (or 5 half-lives, whichever is longer) prior to check-in and until completion of the follow-up visit, unless deemed acceptable by the investigator (or designee);
  • Has used any prescription medications (excluding hormone replacement therapy, oral, implantable, transdermal, injectable, or intrauterine ), including systemic antimicrobial therapies, within 30 days (or 5 half-lives, whichever is longer) before dosing or during the study (ie, through the follow-up visit);
  • Positive antibody;
  • History of diabetes mellitus.

For Participants with Hepatic Impairment-

  • Participants receiving strong and moderate cytochrome P450 (CYP) 3A inhibitors that have not been stopped for ≥5 days or a time frame equivalent to 5 half-lives (whichever is longer), or strong and moderate inducers that have not been stopped for ≥4 weeks or a time frame equivalent to 5 half-lives (whichever is longer), before administration of the study drug;
  • Participants with Grade 2 or higher encephalopathy, as defined by the grading scale in the Food and Drug Administration (FDA) guidance on PK studies in participants;
  • Participant has a portal systemic shunt;
  • Participant demonstrates evidence of hepatorenal syndrome;
  • Participant has required treatment for gastrointestinal bleeding within the 3 months prior to check-in (Participants demonstrating banding procedure within 1 month prior to check-in may be included at the discretion of the investigator [or designee]);
  • Participant has required new medication or a change in dose for hepatic encephalopathy within 3 months prior to check-in, unless approved by the investigator (or designee);
  • Participants who require paracentesis within 3 months prior to check-in or planned during the study;
  • Clinical evidence of moderate to severe ascites;
  • Any evidence of progressive liver disease (between screening and check-in) as indicated by liver transaminases, alkaline phosphatase, or gamma-glutamyl transferase, or a ≥50% worsening of serum bilirubin or prothrombin time.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Mitapivat

    Mitapivat tablet as a single oral dose, under fasted conditions on Day 1 to compare participants with normal hepatic function to participants with moderate hepatic function (Child-Pugh \[C-P\] Score B, score of 7 to 9).

    Drug: Mitapivat

Interventions

  • Mitapivat tablets

    Also known as: AG-348, AG-348 sulfate hydrate, Mitapivat sulfate

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time 0 (Predose) to Extrapolated to Infinity Time (AUC∞) of Mitapivat

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 17

  2. Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUC0-t) of Mitapivat

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 17

  3. Maximum Plasma Concentration (Cmax) of Mitapivat

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 17

Secondary outcomes

  1. Time to Reach Cmax (tmax) of Mitapivat

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 17

  2. Terminal Elimination Half-life (t1/2) of Mitapivat

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 17

  3. Apparent Total Clearance (CL/F) of Mitapivat

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 17

  4. Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Mitapivat

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 17

  5. Fraction Unbound (fu) for Mitapivat in Plasma

    Time frame: Pre-dose and at multiple timepoints post-dose up to Day 11

  6. Number of Participants With Adverse Events (AEs), AEs by Severity, and Relatedness to Study Treatment

    Time frame: Up to Day 17

  7. Number of Participants With Abnormalities in Laboratory Evaluations, Based on Coagulation, Hematology, Clinical Chemistry and Urinalysis Test Results

    Time frame: Up to Day 12

  8. Number of Participants With Changes in 12-lead Electrocardiogram (ECG) Parameters

    Time frame: Up to Day 12

  9. Number of Participants With Changes in Vital Sign Measurements

    Time frame: Up to Day 12

  10. Number of Participants With Changes in Physical Examination Findings

    Time frame: Up to Day 12

07

Study locations

3 sites
  • Orange County Research Center (OCRC)
    Tustin, California 92780, United States
  • Clinical Pharmacology of Miami (CPMI)
    Miami, Florida 33014, United States
  • Orlando Clinical Research Center (OCRC)
    Orlando, Florida 32809, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Jul 2023, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2022
First posted
Nov 9, 2022
StartActual
Jan 10, 2023
Primary completionActual
Jul 21, 2023
CompletionActual
Jul 21, 2023
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05610657
Responsible party
Sponsor
First posted
Nov 9, 2022
Start date
Jan 10, 2023
Primary completion
Jul 21, 2023
Completion
Jul 21, 2023
Last update
Sep 21, 2023

Study contacts

Medical Affairs
study chair · Agios Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mitapivat

Start the discussion